Celcuity (NASDAQ:CELC – Get Free Report) and Zicix (OTCMKTS:ZICX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations for Celcuity and Zicix, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Celcuity | 0 | 0 | 6 | 1 | 3.14 |
Zicix | 0 | 0 | 0 | 0 | N/A |
Celcuity presently has a consensus target price of $28.67, suggesting a potential upside of 64.28%. Given Celcuity’s higher probable upside, research analysts clearly believe Celcuity is more favorable than Zicix.
Institutional and Insider Ownership
Volatility and Risk
Celcuity has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Comparatively, Zicix has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.
Earnings and Valuation
This table compares Celcuity and Zicix’s gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Celcuity | N/A | N/A | -$63.78 million | ($2.78) | -6.28 |
Zicix | N/A | N/A | N/A | N/A | N/A |
Profitability
This table compares Celcuity and Zicix’s net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Celcuity | N/A | -61.66% | -43.51% |
Zicix | N/A | N/A | N/A |
Summary
Celcuity beats Zicix on 5 of the 8 factors compared between the two stocks.
About Celcuity
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.
About Zicix
Zicix Corporation, through its subsidiary, Texas Mobile Health, Inc., provides diagnostic medical imaging services in Houston, Texas. It offers cardiac diagnostic services, including echocardiogram, stress testing, carotid ultrasound, and halter and event monitoring services; medical services, such as general medical care, medical care for home health patients, general and immigration physicals, weight reduction, cold laser pain relief treatment, physical therapy, and anti-aging treatment; and MRI, CT, and X-Ray services. The company was formerly known as Bederra Corporation and changed its name to Zicix Corporation on February 8, 2011. Zicix Corporation was founded in 1979 and is based in Houston, Texas.
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.